Condition: Non-Muscle Invasive Bladder Urothelial Carcinoma · Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma · Sponsor: University of Wisconsin, Madison
This phase I trial evaluates the effects of bicalutamide, compared to no study drug (NSD), on epidermal growth factor receptor (EGFR) protein expression in patients with non-muscle invasive bladder cancer. Bicalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called EGFR on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if bicalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Arizona Cancer Center - Prevention Research Clinic | Tucson, Arizona, United States | Recruiting |
| Cedars Sinai Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| National Cancer Institute Urologic Oncology Branch | Bethesda, Maryland, United States | Not Yet Recruiting |
| University of Rochester | Rochester, New York, United States | Not Yet Recruiting |
| Ohio State University Comprehensive Cancer Center | Columbus, Ohio, United States | Not Yet Recruiting |
| University of Wisconsin Carbone Cancer Center - University Hospital | Madison, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05521698